

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/38130</b> <b>(43) International Publication Date:</b> 16 October 1997 (16.10.97)
<b>(21) International Application Number:</b> PCT/GB97/00949 <b>(22) International Filing Date:</b> 4 April 1997 (04.04.97) <b>(30) Priority Data:</b> 9607440.6 10 April 1996 (10.04.96) GB <b>(71) Applicant (for all designated States except US):</b> MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> XU, Weiming [GB/GB]; 30 Brimley Road, Cambridge CB4 2DL (GB). <b>(74) Agent:</b> KEITH W. NASH & CO.; 90-92 Regent Street, Cambridge CB2 1DP (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ANALYSIS OF DNA		
<b>(57) Abstract</b>  A novel highly polymorphic DNA marker based on the pentanucleotide repeat (CCTTT/GGAAA) <sub>n</sub> has been identified in the human inducible nitric oxide synthase (iNOS) gene. Twelve different alleles, having between 7 and 18 contiguous repeats, have been identified. The repeat is highly polymorphic in the human population and so lends itself to use as a microsatellite marker with uses in, for example, forensic medicine, population studies, family linkage studies and disease diagnosis.		

BEST AVAILABLE COPY



*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



**Title: Analysis of DNA****Field of the Invention**

This invention concerns analysis of DNA particularly for examining genetic markers, which is useful in, for example, forensic medicine, population studies, family linkage studies and disease diagnosis.

**Background to the Invention**

It is known that there are simple nucleotide sequences in the human genome that can occur in different numbers of repeats in different individuals, giving rise to a range of different alleles or variants of different length that can be used as genetic markers to typify the DNA of an individual.

Tandem repeat minisatellite and microsatellite regions in vertebrate DNA frequently show high levels of allelic variability in the number of repeat units. These highly informative genetic markers have found widespread applications in population genetics, forensic science, medicine and other natural scientific studies. For example, these markers can be used for linkage analysis, determination of kinship in paternity and immigration disputes and for individual identification in forensic medicine. In a minisatellite system, a core DNA sequence unit is usually 15 or more base pairs. To date most studies and applications of such systems have relied on Southern blot estimation of allele length, which requires at least 50ng of relatively undegraded DNA. It is often very difficult to extract such large amounts of DNA from many forensic samples such as blood and semen stains.

Microsatellites, on the other hand, are short tandemly repeated (STR) polymorphic DNA sequences which are most commonly in the form of dinucleotide repeats such as (dC-dA)<sub>n</sub>, but can also be trinucleotide and tetranucleotide repeats. For a further discussion, see Pena, S.D.J. and Chakraborty, R. (1994), Paternity testing in DNA era. Trends in Genetics Vol.10, 204-209. Microsatellites can be amplified using the polymerase chain reaction (PCR) and the resulting amplicons normally range from 80-800 base pairs (bps) in length and so are well suited to processing in automated sequencing machines which are



now widely used for gene scanning and typing. (See Reed, P.W. et al (1994), Chromosome-specific microsatellite sets for fluorescence based, semiautomatic genome mapping. Nature Genet. 7,390-395.) To date, most microsatellite polymorphisms have been based upon dinucleotide repeats. Because of the very small size difference between adjacent alleles, some of the results can be difficult to interpret. Tri and tetranucleotide repeats are easier to use but occur less frequently in the human genome. Expansion of trinucleotide repeat sequences has also been implicated in a number of genetic diseases, including Huntingdon's disease, fragile X syndrome and myotonic dystrophy.

The present invention is based on the discovery in the human inducible nitric oxide synthase (iNOS) gene of a pentanucleotide repeat (CCTTT/GGAAA)<sub>n</sub>. The repeat is located approximately 2.8kb 5' end of upstream promoter region of the iNOS gene on 17q11.1-q11.2. Investigations have shown this pentanucleotide repeat (which is referred to for convenience as Xu-1) occurs in widely varying numbers in different individuals: so far, 12 different variants or alleles have been detected, having between 7 and 18 contiguous Xu-1 repeats. The different alleles are referred to as A7, A8.....A18. Because the Xu-1 repeat is highly polymorphic in the human population, the repeat lends itself to use as a microsatellite marker with uses in, for example, forensic medicine, population studies, family linkage studies and disease diagnosis.

### Summary of the Invention

In one aspect the present invention provides an a method of analysing a sample of DNA to determine the number of contiguous repeats of the sequence (CCTTT/GGAAA) in the iNOS gene.

The number of repeats is typically in the range 7 to 18.

By analysing DNA in this way, a determination can be made of the number of Xu-1 repeats in a particular DNA sample, that is which allele or alleles (usually one or more of A7 to A18) are present.

The sample may be, for example, a sample of blood, semen, saliva, buccal cells or any



other suitable biological material.

Because the Xu-1 repeat is a pentanucleotide repeat, it is easier to distinguish adjacent alleles simply on the basis of size than is the case for smaller repeating units. Experiments have also shown that there is considerable variation in the two alleles (one from each chromosome) of different individuals. The heterozygosity has been calculated as 0.841. The Xu-1 repeat is therefore highly polymorphic and hence has significant value as a genetic marker (the Xu-1 marker) that is easy to use.

Samples are conveniently analysed by use of the polymerase chain reaction (PCR), enabling the method of the invention to be performed on small quantities of sample. A pair of PCR primers has been designed for this purpose, generating products in the range about 170 to 225 base pairs (bp) in size. The forward primer is 5'-ACCCCTGGAAGCCTACAAGTGCAT - 3' (Seq. ID No. 1). The reverse primer is 5'-GCCACTGCACCCTAGCCTGTCTCA - 3' (Seq. ID No. 2).

The resulting products may be sequenced to determine the number of Xu-1 repeats. Alternatively, fragment length can simply be determined, eg by running on an electrophoretic gel, enabling calculation of the number of Xu-1 repeats.

Heterozygosity can be increased substantially by using the Xu-1 marker in conjunction with another genetic marker. For example, good results have been obtained using the Xu-1 marker with a known microsatellite marker based on the polymorphic trinucleotide repeat (ATT/TAA) present in the neuronal nitric oxide synthase (NOS1) gene in repeat numbers ranging from 5 to 13. PCR primers have been designed for use with the NOS1 marker to generate products in the range 110 to 138bp (ie distinct in size from the Xu-1 marker products), that can be used under the same PCR conditions as the Xu-1 primers. The forward primer is 5'-GAAATTGGTCATAGTGGGAATG - 3' (Seq. ID No. 3). The reverse primer is 5'-GTGTTGGTGAACCAACCCTCCTAA - 3' (Seq. ID No. 4).

PCR reactions for the 2 markers can thus be run together, and by using different labels (eg green and blue) for the primers, the PCR products can be detected simultaneously on



the same gel. By using these 2 markers together, heterozygosity is increased to about 99%.

Experiments have shown that there are significant differences in the distribution of alleles with different numbers of the Xu-1 repeat in different ethnic groups. The Xu-1 marker may therefore be of value in population studies, immigration disputes, paternity determination and forensic studies.

Furthermore, because the Xu-1 marker is located in the 5' end of human iNOS gene, which has been implicated in certain common human diseases, such as Alzheimer's disease, hypertension, diabetes and cancers, the marker can be used in allelic association studies and mutation analysis for the diseases. For example, a strong allelic association has already been detected between the repeat number and the senile dementia Lewy body (SDLT) variant of Alzheimer's disease, which represents about one quarter of all cases of Alzheimer's disease. Mutations in flanking sequences have also been detected in some cases of colon cancer. The iNOS gene is also involved in tissue transplantation. The polymorphic marker described in this invention also could be used in genotype typing for tissue transplantation.

The invention will be further described, by way of illustration, in the following Examples and by reference to the accompanying Figures in which:

Figure 1A is a restriction map of the 5' end upstream region of the human inducible nitric oxide synthase (iNOS) gene, including the Xu-1 repeat region;

Figure 1B shows the sequence of a 383 base pair PstI fragment (the upper strand of which is Seq. ID No. 5) included in Figure 1, with PstI sites underlined and 11 contiguous Xu-1 repeats marked by boxes;

Figure 2 shows an electrophoretic gel showing different Xu-1 alleles from different individuals;



Figure 3 is a family tree and electrophoretic gel showing different Xu-1 alleles from different family members;

Figure 4 shows various family trees, with Xu-1 allele data;

Figure 5 shows an electrophoretic gel showing different Xu-1 alleles in combination with another microsatellite marker for different individuals;

Figure 6 is a chart showing the distribution of different Xu-1 alleles (A8 to A15) for a number of normal individuals, autopsied patients with the senile dementia Lewy body (SDLT) variant of Alzheimer's disease and non-Lewy body type Alzheimer's patents (AD) with the x axis showing % of chromosomes and the y axis showing the allele numbers; and

Figure 7 is a chart similar to Figure 6 showing the distribution of different Xu-1 alleles (A8 to A18) in Caucasian, Black, Chinese and Gujerati Asian populations.

### Example 1

The new pentanucleotide repeat, (CCTTT/GGAAA)<sub>n</sub> on which the present invention is based was identified from a cosmid clone, pCOS4 (described by Xu, W., Charles, I., Moncada, S., Gorman, P., Sheer, D., Liu, L., and Emson, P.C. (1994) in Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the pericentric region of chromosome 17 and to chromosome 7, respectively. Genomics 21, 419-422), which contained a 35kb human genomic insert, which has also been shown to contain the human inducible nitric oxide synthase (iNOS) gene coding region and its promoter region. A restriction map of the 5' upstream end of the gene is shown in Figure 1A. In order to clone human promoter region of the inducible nitric oxide synthase gene, the cosmid was shot-gun cloned with PstI and HindIII restriction enzymes into pBluescript-SK vector. Subclones were then sequenced using an ABI automatic sequencer with M13 universal and reverse primers. One of the PstI subclones, clone number 512, has been shown by sequencing studies to contain eleven perfect contiguous pentanucleotide repeats, (CCTTT/GGAAA)<sub>11</sub>, that is a stretch of fifty-five bases pairs of human genome.



located 2.8kb of 5' end of the major transcription initiation site of the human inducible nitric oxide synthase gene. The sequence of this 383 base pair fragment (Seq. ID No. 5) is shown in Figure 1B, with the 11 pentanucleotide repeats marked in boxes. It will be seen that the repeats and flanking regions constitute polypurines in one strand and polypyrimidines in the other strand spanning over 130 base pairs, which is highly unusual in a microsatellite because of the instability of such sequences.

### Example 2

A pair of specific oligonucleotide primers were designed to use the polymerase chain reaction (PCR) directly to amplify the polymorphic pentanucleotide repeat from the genomic DNA from a range of human DNA samples.

The DNA can be isolated from either blood or buccal cells of the saliva or any other biological sources which containing nuclei. The DNA extraction can be done in all cases using standard SDS-Proteinase K-Phenol procedure. (Sambrook, J., Fritsch, E.F. & Maniatis, T.(1989). Molecular cloning. Laboratory manual Cold Spring Harbor Laboratory Press, New York.)

A pair of flanking PCR primers designed to amplify the genomic DNA from human blood genomic DNA were as follow: The forward primer is 5'-ACCCCTGGAAGCCTACAACCTGCAT - 3' (Seq. ID No. 1). The reverse primer is 5'-GCCACTGCACCCTAGCCTGTCTCA - 3' (Seq. ID No. 2). The primers are double underlined in Figure 1B. The forward primer is 5' end labelled with fluorescent dye 6-carboxyfluorescein (6-Fam)(Oswel DNA Services, University of Southampton, Southampton SO16 7PX) or Hex phosphoramidites (Applied Biosystems). Primers were synthesised, labelled and HPLC-purified using standard methods (Oswel DNA Services, Southampton).

The PCR protocol is as follows:

#### i) Reagent Mixture

The following reagents were mixed in a labelled 0.5ml double-snap-cap microcentrifuge



tube:

<u>Reagent</u>	<u>Amount</u>
Template	1 $\mu$ l 50-200ng Genomic DNA
10 x PCR buffer II (Cetus, N808-0010, E8064)	5 $\mu$ l
dNTP Mix (2.5mM each, Pharmacia, 27-2035-01)	5 $\mu$ l
25mM MgCl <sub>2</sub> (Cetus, N808-0010, E 0843)	3 $\mu$ l
Forward primer (200 $\mu$ g/ml, 6 Fam labelled)	1 $\mu$ l
Reverse primer (200 $\mu$ g/ml)	1 $\mu$ l
dH <sub>2</sub> O (distilled or deionized water)	33.5 $\mu$ l
AmpliTaq DNA polymerase (Cetus, N801-0060)	0.5 $\mu$ l (2.5 Units)
Final Reaction Volume	50 $\mu$ l

(AmpliTaq is a Trade Mark of Roche Molecular Systems, Inc.)

(dNTP = deoxynucleotide triphosphate. Taq DNA polymerase = DNA polymerase isolated from *Thermus aquaticus*.)

The reaction mixture was overlaid with one drop of mineral oil (Sigma No. M5904) (approximately by 40 $\mu$ l).

## ii) PCR Reaction

PCR is carried out using a Perkin Elmer Cetus Model 480 (or equivalent machine) as follows:

1. Place the tubes in a thermal cycler.
2. Immediately after placing the tubes in the thermal cycler, begin thermal cycling as follows:
  - a) preheat to 96°C
  - b) 96°C for 30 seconds
  - c) 30 cycles as follows: 94°C for 1 min., annealing at 50°C for 1 min., and polymerising at 72°C for 1 min.
  - d) 72°C for 10 min.
3. Rapid thermal ramp to 4°C and hold.



The sizes of the PCR products range from about 170bp to 225bp, dependent on the number of pentanucleotide repeat units.

### iii) Electrophoresis

The PCR products are then loaded directly on an Applied Biosystems Model 373A DNA Sequencer using 6%-urea polyacrylamide gel. Running conditions are at 2000V, 26 watts for 4 to 12 hours. The GENESCAN option is used to start running the gel. (Genescan is a Trade Mark of Applied Biosystems, Inc.)

Preparing and loading the samples was carried out as follows:

1. Prepare a mixture of the following reagents:
  - 5  $\mu$ l deionized formamide
  - 0.5  $\mu$ l Rox labelled DNA marker (GENESCAN-2500)
2. Add 4  $\mu$ l of this mixture to each tube and agitate vigorously. Centrifuge the solution briefly.
3. When the gel is ready for loading, heat the samples at 90°C for 2 minutes to denature, then transfer them immediately onto ice.
4. Load the samples onto an Applied Biosystems 373A DNA Sequence according to the instructions in the User's Manual.

### iv) Genescan and Analysis

The GENESCAN 672 software is used to collect and analyse the data automatically. This software can be used not only to collect electrophoretic data across all 24 or 36 lanes, but also accurately to identify and analyse the different lanes of the fragments. The internal standard, Rox-GENESCAN 2500, permits accurate and precise base identification and accurate sizing of the fragments. If an automatic DNA sequencer is not available, other methods such as use of radioactive labels can be used instead to detect the PCR products.

### v) Sequence Analysis

The PCR products can also be cloned into the Bluescripts pKS+ vector using the T-vector cloning system (Stratagene, Cambridge, UK) and sequenced by TaqDyeDeoxy terminator cycle sequencing with an Applied Biosystems Model 373A DNA Sequencer, using vector



universal and reverse primers. The products can also directly sequenced using the PCR DNA gel purification system from Qiegen, following the manufacturers instructions, with 3pmol of Primer A or B.

### **Example 3**

Using the primers and techniques described in Example 2, DNA from 36 unrelated individuals was examined. The resulting electrophoretic gel is shown in Figure 2. A series of (red) bands (not visible in the Figure) show internal DNA size markers (Genescan 2500, Rox), as indicated on the left of the Figure. The brighter (blue) bands across the middle of the gel are produced by 6-Fam fluorescently labelled primer A, and these show the presence of different repeat lengths, demonstrating polymorphism.

### **Example 4**

Data was obtained in a similar manner from 3 generations of a Caucasian (CEPH (Centre Etude Polymorpisme Humain)/Amish) family (pedigree 884). The results are shown in Figure 3 in the form of a family tree and gel data showing Xu-1 allele data. The results are fully consistent and show Mendelian co-dominant inheritance. Other family groups have been similarly analysed and all show the same Mendelian co-dominant inheritance manner of this locus. For example, Figure 4 shows the genotypes of four large CEPH families (pedigrees 884, 1424, 1341 and 1349).

### **Example 5**

By using a probe for the Xu-1 repeat in conjunction with a probe for another genetic marker, more detailed specific genetic information can be obtained about an individual, that is, a more detailed "genetic fingerprint" can be obtained, resulting in increased heterozygosity and hence usefulness of the results. Experiments were carried out using probes for the Xu-1 repeat as described above, in conjunction with probes for a known trinucleotide repeat (ATT/TAA) present in the neuronal nitric oxide synthase (NOS1) gene in repeat numbers ranging from 5 to 13. The NOS1 repeat is described by Chung, E., Curtis D., Chen, G., Marsden, P.A., Twells, R., Xu, W. and Gardener, M. (1996) in Genetic evidence for the neuronal nitric oxide synthase gene as a susceptibility for infantile pyloric stenosis, Am.J. Hum. Genet. 58,363-370.



For this purpose, PCR primers were designed for use with the NOS1 marker to give products in the range 110 to 138bp, fluorescently labelled green with 5-Hexdye. The forward primer is 5'- GAAATTGGTCATAGTGGGAATG - 3' (Seq. ID No. 3). The reverse primer is 5'- GTGTTGGTGAACCAACCCTCCTAA - 3' (Seq. ID No. 4). This pair of the primers can be used under exactly the same PCR conditions as the primers for the Xu-1 repeat labelled with Famdye, so two PCR reactions can be performed at the same time.

Figure 5 shows a Genescan gel obtained by this procedure, with the upper (blue) bands showing the Xu-1 repeats and the lower (green) bands the NOS1 repeats with results aligned for each sample. The combined heterozygosity is about 99%.

#### Example 6

Because the Xu-1 repeat of the invention is located at the 5' end of the human iNOS gene, which has been implicated in certain diseases including Alzheimer's disease, experiments were carried out on 112 deceased demented patients diagnosed by autopsy as having Alzheimer's disease, both the senile dementia Lewy body (SDLT) variant of Alzheimer's disease (22 patients) and non-Lewy body type (AD) (90 patients). For comparison, results were also obtained from 101 normal Caucasian individuals. The DNA for all subjects was obtained from the Cambridge Brain Bank and was approved by the local ethics committee. Experiments were performed generally as described in Example 2.

The results are shown graphically in Figure 6. The results show that most alleles have similar frequency in patients with Alzheimer's disease and non-demented controls. However, in samples from the SDLT patients, two smaller alleles, A8 and A9 (having 8 and 9 pentanucleotide repeats, respectively) are over-represented (16%, compared to normal 3% and AD 4%) and the A11 allele is under-represented (2% compared to normal 19%). Using the counting program from Linkage Utility, the p-value is calculated to be 0.0151 (6 degree freedom), which is much lower than required value 0.05 (5%). The results suggest that certain combinations of the Xu-1 pentanucleotide repeat variant in iNOS gene promoter, namely high A11 allele and/or low A8 and A9 alleles, may be associated with development of SDLT. This information may be of diagnostic or



predictive value.

### Example 7

Experiments were carried out in similar manner on 271 individuals (ie 542 chromosomes) of Caucasian, Black (Afro Caribbean and Afro American), Chinese and Gujarati Asian ethnic origin and the distribution of different numbers of the Xu-1 repeat were analysed by ethnic group. The results are shown in tabular form in Tables 1 and 2, and graphically in Figure 7. The degree of polymorphism is characterised by two indices: Heterozygosity (Heter) and polymorphism information content (PIC). For formulas and explanation, see Botstein, D., White, R.L. Skolnick, M. and Davis, R.W. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. *Am.J.Hum.Genet.* 32:314-331.(1980). The overall heterozygosity was 0.841.

There are significant differences in allelic frequency of distribution apparent between the different ethnic groups. These results may therefore be of forensic value.

**Table 1**

(CCTTT) <sub>n</sub>	Size (bp)*	Caucasian	Black	Chinese	Gujaratis	Combined
8	175	0	1(0.006)	0	0	1(0.002)
9	180	7(0.035)	9(0.058)	0	5(0.035)	21(0.039)
10	185	25(0.124)	19(0.123)	13(0.31)	20(0.139)	77(0.142)
11	190	38(0.188)	14(0.09)	4(0.10)	23(0.16)	79(0.146)
12	195	59(0.292)	37(0.24)	9(0.21)	29(0.20)	134(0.247)
13	200	47(0.233)	28(0.181)	2(0.05)	23(0.16)	100(0.184)
14	205	20(0.10)	19(0.123)	6(0.14)	17(0.12)	62(0.114)
15	210	5(0.035)	25(0.162)	3(0.07)	20(0.14)	53(0.098)
16	215	1(0.005)	2(0.013)	1(0.02)	5(0.035)	9(0.017)
17	220	0	0	3(0.07)	1(0.007)	4(0.007)
18	225	0	0	1(0.02)	1(0.007)	2(0.004)
Total		202	154	42	144	542
No. of alleles		8	9	9	10	11
Heterozygosity		0.802	0.846	0.835	0.859	0.841
PIC		0.769	0.82	0.793	0.835	0.81901

\* Due to flanking sequences and running condition, size varies  $\pm 2$ bp.



Table 2

Population A:	Population B:	d.f.	X <sup>2</sup>	P value
Caucasian:	Black	7	30.05	0.000083
Caucasian:	Chinese	7	34.89	0.000012
Caucasian:	Gujeratis	7	27	0.000235
Black:	Chinese	7	32.16	0.000038
Black:	Gujeratis	7	8.46	0.2938
Chinese:	Gujeratis	7	14.65	0.0407



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: Medical Research Council  
(B) STREET: 20 Park Crescent  
(C) CITY: London  
(E) COUNTRY: United kingdom  
(F) POSTAL CODE (ZIP): W1N 4AL  
(G) TELEPHONE: (0171) 636 5422  
(H) TELEFAX: (0171) 323 1331

(A) NAME: Xu, Weiming  
(B) STREET: 30 Brimley Road  
(C) CITY: Cambridge  
(E) COUNTRY: United Kingdom  
(F) POSTAL CODE (ZIP): CB4 2DL

(ii) TITLE OF INVENTION: Analysis of DNA

(iii) NUMBER OF SEQUENCES: 5

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ACCCCTGGAA GCCTACAACT GCAT

24

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCCACTGCAC CCTAGCCTGT CTCA

24



## (2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAAATTGGTC ATAGTGGGAA TG

22

## (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GTGTTGGTGA ACCAACCCTC CTAA

24

## (2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 383 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CTGCAGCAAG CCATAACAT TCCNTGGAG AAAGATGCTT TCCCAGCATC AAGATGAGAA	60
GATAACTTTT ATCAGCTCAG AGATGGCACC AGAGCCATCT ACAAATACCA AACAAACCTT	120
GCTATCCTAC TCCTTAGCTC ACTTCCACAT GTTTACCTTC TCACAGCTTG CCACCCCTGG	180
AAGCCTACAA CTGCATTGCT CTTGTACCT TTCTCTTCTT TCTTTCTTTC TCTCTTTCCT	240
TTCTTTTCTT TTCTTTTCCT TTCTTTTCCT TTCTTTTCCT TTCTTTTCCT TTCTTTTCCT	300
TTCTTTTCCT CCTTTCCCTC TTTTTTTTCC TTTTTTTTTT GAGACAGGCT AGGGTGCAGT	360
GGCGCGACCA TAGCTCTCTG CAG	383



CLAIMS

1. A method of analysing a sample of DNA to determine the number of contiguous repeats of the sequence (CCTTT/GGAAA) in the iNOS gene.
2. A method according to claim 1, wherein samples are analysed by use of the polymerase chain reaction (PCR).
3. A method according to claim 2, using as PCR primers a forward primer having the sequence 5'- ACCCCTGGAAGCCTACAACCTGCAT - 3' (Seq. ID No. 1) and a reverse primer having the sequence 5'- GCCACTGCACCCTAGCCTGTCTCA - 3' (Seq. ID No. 2).
4. A method according to any one of the preceding claims, comprising further analysing the sample of DNA to determine the characteristics of a further genetic marker.
5. A method according to claim 4, wherein the further genetic marker is based on the polymorphic trinucleotide repeat (ATT/TAA) present in the neuronal nitric oxide synthase (NOS1) gene.
6. A method according to claim 5, using further PCR primers including a forward primer 5'- GAAATTGGTCATAGTGGGAATG - 3' (Seq. ID No. 3) and a reverse primer 5'- GTGTTGGTGAACCAACCCTCCTAA - 3' (Seq. ID No. 4).
7. PCR primers comprising forward primer 5'- ACCCCTGGAAGCCTACAACCTGCAT - 3' (Seq. ID No. 1) and reverse primer 5'- GCCACTGCACCCTAGCCTGTCTCA - 3' (Seq. ID No. 2).
8. PCR primers comprising forward primer 5'- GAAATTGGTCATAGTGGGAATG - 3' (Seq. ID No. 3) and reverse primer 5'- GTGTTGGTGAACCAACCCTCCTAA - 3' (Seq. ID No. 4).



1/10

Restriction map of 5' end upstream region of human inducible nitric oxide synthase gene and ( CCTTT/GGAAA )<sub>n</sub> repeat region in 383 bp of PstI fragment




Fig. 1A



60 CTGCAGCAAG CCATAAACAT TCCCNTGGAG AAAGATGCTT TCCCAGCATC AAGATGAGAA  
 GACGTCGCTC GGTATTGTA AGGNACCTC TTTCTACGAA AGGTCGTAG TTCTACTCTT  
 120 GATAACTTTT ATCAGCTCAG AGATGGCACC AGAGCCATCT ACAATAACCA AACAAACCTT  
 CTATTGAAAA TAGTCGAGTC TCTACCGTGG TCTCGGTAGA TGTTTATGGT TTGTTTGGAA  
 180 GCTATCCTAC TCCTTAGCTC ACTTCCACAT GTTTACCTTC TCACAGCTTG CCACCCCTGG  
 CGATAGGATG AGGAATCGAG TGAAGGTGTA CAAATGGAAG AGTGTCGAAC GGTGGGACC  
 240 AAGCCATCAA CTGCATTTCGT CTGTGACCTT TTCTCTTCTT TCTTTCTTTC TCTCTTTCCT  
TTCCGGATGTT GACGTAAGCA GAACAGTGGA AAGAGAAGAA AGAAAGAAAG AGAGAAAGGA  
 300 TTCCCTTTCTT TTCCCTTTCCT TTCCCTTTCCT TTCCTTTCCT TTCCTTTCCT  
 AAGGAAAGAA AAGGAAAGGA AAGGAAAGGA AAGGAAAGGA AAGGAAAGGA  
 360 TTCCCTTTTCCT CCTTCCCTC TTTTTTTCC TTTTTTTTCCT GAGACAGGCT AGGTGTCAGT  
AAGGAAAGGA GGAAAGGGAG AAAAAAAGG AAAAAAAA CTCTGTCCGA TCCCACGTCA

383

GGCGCGACCA TAGCTCTCTG CAG  
CCGCGCTGGT ATCGAGAGAC GTC

Fig. 1B



3/10




Fig. 2

SUBSTITUTE SHEET (RULE 26)



4/10

CEPH/AMISH Pedigree 884  
iNOS CTTT repeat




Fig. 3



5/10

# CEPH / Amish Pedigree 884





Fig. 4 Sheet 1



6/10

## CEPH / Utah Pedigree 1349



## CEPH / Utah Pedigree 1341




Fig. 4 Sheet 2



7/10

## CEPH/Utah Pedigree 1424





Fig. 4 Sheet 3



8/10

Fig. 5





9/10




Fig. 6

SUBSTITUTE SHEET (RULE 26)



10/10


Distribution of the CCTTT repeats in human populations

Fig. 7



# INTERNATIONAL SEARCH REPORT

Inventor's Application No  
PCT/GB 97/00949

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HUM. HERED., vol. 45, - 1995 pages 301-302, XP002035064 NAKAYAMA T. ET AL., : "CA repeat polymorphism of the endothelial nitric oxide synthase gene in the japanese" see the whole document	1-8
A	CA 2 013 430 A (OREGON HEALTH SCIENCE UNIVERSITY) 29 September 1991 see the whole document --- -/-	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

11 July 1997

Date of mailing of the international search report

23.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Müller, F



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/00949

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PROC. NATL. ACAD. SCI. USA, vol. 90, - April 1993 pages 3491-3495, XP002035065 GEILER D. A. ET AL.,: "Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes" see the whole document ---	1-8
P,X	KAWASAKI MED. J., vol. 22, no. 2, - 1996 pages 51-56, XP002035066 TOMITA M. ET AL., : "Variable number of tandem repeat polymorphism of the endothelial nitric oxide synthase gene in japanese population" see the whole document -----	1-8



## INTERNATIONAL SEARCH REPORT

### Information on patent family members

Institutional Application No

PCT/GB 97/00949

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2013430 A	29-09-91	NONE	



This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.



**THIS PAGE BLANK (USPTO)**